Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Promoting pharmacy to MPs: PSNC and others to host roundtable events
Over the next fortnight PSNC and the other national community pharmacy representative bodies will be making the case for pharmacy at both the Labour and Conservative Party Conferences. PSNC, the Association of Independent Multiple Pharmacies (AIM), the Company Chemists’ Association (CCA) and the National Pharmacy Association (NPA) are jointly hosting roundtable events at both conferences...
Brexit: Important update for pharmacies
As we head towards the UK’s planned exit from the European Union, the Government’s guidance and messaging for the public and those involved in the medicines supply chain has evolved. Below is a round-up of recent events that community pharmacy teams need to be aware of. Patient messaging revised The patient information about a no-deal...
September 2019 Price Concessions – 1st update
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price concession Betahistine 8mg tablets 84 £1.65 Betahistine 16mg tablets 84 £2.99 Co-careldopa 12.5mg/50mg tablets 90 £10.73 Cyclizine 50mg/1ml solution for injection ampoules 5 £14.00 Escitalopram 10mg tablets 28 £3.19 Ibandronic acid 150mg tablets 1...
Shortage Notice: Fluoxetine 10mg, 30mg and 40mg capsules
Morningside and Advanz, the manufacturers of Fluoxetine 10mg, 30mg and 40mg capsules, are currently experiencing temporary disruptions. Please see a table below which summarises the overall fluoxetine availability: Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘Special Order’ and...
CPCS Toolkit published
The NHS Community Pharmacist Consultation Service (CPCS) will commence on 29th October 2019 and the Toolkit to support pharmacy teams to provide the service has just been published on the NHSBSA website. The Toolkit has been developed by NHS England and NHS Improvement (NHSE&I), with input from the Urgent Care Delivery and Implementation Group (a group of...
Shortage Notice: Provera (medroxyprogesterone acetate) 100mg tablets
Pfizer, the sole supplier of Provera tablets, are experiencing manufacturing delays, and are out of stock of the 100mg tablets until week ending 8th November 2019. Provera 200mg and 400mg tablets remain available, but Pfizer say ‘they are unable to bridge the gap without going out of stock’. For guidance on alternative agents and management...
Contractor notice: Clarification on dental prescription reimbursement
It has come to PSNC’s attention that inaccurate information has been circulating about the processing and reimbursement of dental prescriptions (FP10D) with stamped drug information. Some pharmacy teams have reported that they had heard that the NHS Business Service Authority (NHSBSA) ignores handwritten quantities on stamped prescriptions unless the quantity specified is initialled or countersigned...
MPs investigate prescription exemption and penalty charge notice system
The Public Accounts Committee (PAC) has today published a report of its investigation into penalty charge notices in healthcare, calling for an overhaul of the system which it considers “not fit for purpose”. The PAC is made up of a group of cross-party MPs; the Committee launched an inquiry after it became concerned that penalty...
Resources available to assist with meeting the diabetes quality criterion from 1st October
PSNC has published Briefing 043/19: Pharmacy Quality Scheme – Foot and eye screening (retinopathy) checks for patients with diabetes to assist community pharmacy contractors with getting ready to meet the diabetes quality criterion of the Pharmacy Quality Scheme (PQS), which contractors need to start working towards from 1st October 2019. The Briefing explains how to...
MHRA Drug Safety Update September 2019
A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 1 August 2019) has been published and includes articles on: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
Xospata leads latest CHMP recommendations
The committee has recommended seven medicines for approval at its September 2019 meeting.
Tresiba lowers risk of hypos in type II diabetes
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
Sertraline improves anxiety, but ‘unlikely’ to treat depression
The findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought.
‘New era’ of precision medicine for children with cancer
only 7% of children with targetable mutations were able to access the appropriate adult drug in a study.
Four Health, ARK top the PM Society Digital Awards 2019
The coveted Pharma Digital Partner award was won by Emma Prosser from MSD.
Fastest drop in smoking rates in over a decade
Adult smoking rates fell 2.2% from January to July 2019, the equivalent of 200 fewer smokers an hour.
Social media sites act on NHS crack down plea
Facebook and Instagram have announced that they will remove posts promoting ‘miracle’ cures and get-slim-quick products.
IAOCR launches patient safety campaign
'Don’t Risk Your Research' aims to raise awareness of the risks incompetence poses to patients, clinical research and organisations.
FDA Breakthrough granted for Roche’s Gazyva
The designation was based on the Phase II NOBILITY study.
Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Cosentyx bags positive results in potential new indication
Novartis has also submitted to the EMA for approval in the disease, non-radiographic axial spondyloarthritis.
NICE recommends Takhzyro
The recommendation was made based partly on data from the HELP-03 Study, in which Takhzyro reduced the mean number of monthly HAE attacks by 87%.
MHRA, Bill & Melinda Gates foundation team up for medicine safety whilst pregnant
Research on the topic is vital yet sparse, as data in this area remain limited.
Happify, Sanofi to advance digital therapeutics for MS
The therapeutics will address key co-morbidities for individuals living with the disease.
Acceleron abandons muscular dystrophy drug
The company will not conduct any further trials.
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/